One engine combining proprietary biology, validated data, AI and high-throughput automation to redefine the speed and scale of antibody discovery.
Fully Human Antibody
Platform
AI Selection Model Trained
on 1B+ Sequences
In Vitro & In Vivo
Validation
To build a scalable fully human antibody library, our proprietary RenMice® suite and target knockout strategy break immune tolerance to unlock the full antibody repertoire, enabling broad coverage of conserved, hard-to-hit epitopes. Furthermore, in vivo negative selection guarantees high target specificity, superior safety and downstream developability.
TAA Projects
Available for easy plug-and-play
Hu-VHH Projects
TFR1, CD98, 4-1BB, CD3, etc.
GPCR Projects
CCR8, GPRC5D, LGR5, CCR2 etc..
Dual-TAA bsADCs
Ready for out-licensing
TCR mimic Projects
GP100, WT1, KRAS, etc..
Autoimmune Projects
OX40, CD40, TNFSF15, etc..
Our proprietary intelligence layer accelerates discovery workflows by combining massive biological datasets with high-throughput NGS and advanced machine learning models.
High hit success, functional relevance
Trained on large-scale, validated fully human antibody data
De-risked, ready-to-scale candidates
Wet-lab results continuously refine AI models
Biology-Grounded AI Engine
From 10 MILLION possibilities to 200 diverse, high-quality candidates - powered by our proprietary biology and AI.
Our RenMice® suite combined with target knockout (KO) strategy, generate antibodies against novel and conserved epitopes that other platforms miss. Negative selection via animal immunization enhances specificity from day one.
Our proprietary AI analyzes billions of real-world binding data to predict developability, specificity, and affinity– selecting the top candidates with the highest potential.
Advanced clustering algorithms remove redundant or highly similar sequences to ensure a diverse set of ~200 unique candidates.
The final 200 diverse, AI-selected candidates are synthesized and tested in the lab for top binders and functional performance.
Built for Difficult Targets
Overcome challenging targets where traditional screening falls short—AI-driven selection expands hit discovery by 20× and enriches high-affinity candidates.
AI-Positive Clones
vs. 282 traditional hits by Beacon
High-Affinity
AI-positive clones (KD≤10nM)
Targets Achieved
>60% High-Affinity Conversion
AI vs. Traditional Hits
On structurally challenging targets
Superior Candidates, Faster Decision
High-affinity, developable antibodies with greater confidence.
Evaluated using SPR-based affinity screening across HCab discovery campaigns.
Median Hit Rate
IQR:68% - 90%Maximum Hit Rate
Across CampaignsNGS & AI Workflow vs. Conventional Screening
End-to-end manufacturing for speed, consistency, and scalability utilizing a 100% hands-free robotic workflow from plasmid to purified therapeutic protein production.
RenSuper™ combines validated biology, first-in-class closed-loop intelligence, and automated manufacturing to bring the industry’s most reliable antibody discovery online.
